New Ovarian Cancer Drug Combination Shows Promise
A study of 33 women shows this combination therapy could provide a new option for treating recurrent ovarian cancer.
Updated on Oct. 29, 2026 in Cancer
Live Poll
If facing a recurrence of cancer, would you prefer trying a new combination therapy?
A phase 1 clinical study found that a combination of the drug sofetabart mipitecan and bevacizumab achieved a 79.3% overall response rate in women with platinum-sensitive ovarian cancer. This experimental therapy is currently being evaluated for patients whose cancer has returned after initial treatments.
Why it matters
Current options for recurrent ovarian cancer often become less effective over time, and existing standards of care have not fully adapted to account for specific tumor genetic profiles. These early results offer a potential new path for patients who have previously been treated with PARP inhibitors.
This phase 1 trial of 33 women with platinum-sensitive ovarian cancer reported an overall response rate of 79.3% and a 100% disease control rate. These are preliminary findings with a median follow-up of 10.18 months; median progression-free survival has not yet been reached.
The players
Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of new medical therapies in the United States.
European Society for Medical Oncology
A global professional organization that hosts major scientific congresses for the presentation of oncology research.
The details
The treatment combines sofetabart mipitecan, which is designed to target specific proteins on cancer cells, with bevacizumab, a well-established therapy that works by inhibiting the growth of new blood vessels that tumors need to survive. By delivering the drug in this dual-action approach, researchers aim to overcome the diminishing efficacy that often occurs with subsequent recurrences. The study reported that common side effects included nausea, fatigue, and neutropenia, with only two patients discontinuing the treatment due to adverse events.
Timeline
January 2026: The FDA granted breakthrough therapy designation to sofetabart mipitecan.
Health Landscape
The development of this combination therapy follows the broader trend of diversifying treatment options for recurrent ovarian cancer beyond traditional platinum-based regimens. It specifically targets a gap in current standards of care where efficacy often declines following prior PARP inhibitor use.
If you are managing recurrent platinum-sensitive ovarian cancer, this experimental combination may be worth discussing with your oncologist to see if future clinical trials might be a suitable option. It is important to remember that these are preliminary results and the treatment is not yet widely available.
The takeaway
While these early results are promising for patients with recurrent ovarian cancer, they represent a small initial cohort that requires further study. Patients should monitor updates on the progress of phase 3 trials to understand when and how this treatment might become an available option.
Further reading
For more information on the current state of treatment, visit our Cancer section.
Source note: This article includes information reported by Healio.
Live Poll
If facing a recurrence of cancer, would you prefer trying a new combination therapy?
